PD-L1 expression was higher in the p53 mutant tumor than in the p53 wild type cancer, and the p53 mutant tumor was highly sensitive to the anti-PD-L1 therapy (Dong et al. 2017). The gene discussed is TP53; the disease is neoplasm.